---
title: "Tibet Aim Pharm. Inc. (002826.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002826.SZ.md"
symbol: "002826.SZ"
name: "Tibet Aim Pharm. Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T00:13:55.968Z"
locales:
  - [en](https://longbridge.com/en/quote/002826.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002826.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002826.SZ.md)
---

# Tibet Aim Pharm. Inc. (002826.SZ)

## Company Overview

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, severe infection, shock, cord injury, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.emyy.cn](https://www.emyy.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.30)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 59 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.74% |  |
| Net Profit YoY | 153.74% |  |
| P/B Ratio | 4.26 |  |
| Dividend Ratio | 0.52% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3567983885.28 |  |
| Revenue | 669677690.57 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.69% | B |
| Profit Margin | 13.94% | B |
| Gross Margin | 82.48% | A |
| Revenue YoY | 4.74% | C |
| Net Profit YoY | 153.74% | A |
| Total Assets YoY | 11.84% | B |
| Net Assets YoY | 9.18% | B |
| Cash Flow Margin | 184.32% | B |
| OCF YoY | 4.74% | C |
| Turnover | 0.64 | B |
| Gearing Ratio | 24.04% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tibet Aim Pharm. Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.74%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "153.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.26",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.52%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3567983885.28",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "669677690.57",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.69%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.94%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "82.48%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "4.74%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "153.74%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "11.84%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.18%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "184.32%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.74%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.04%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 38.18 | 86/215 | 93.10 | 46.96 | 41.43 |
| PB | 4.26 | 173/215 | 5.04 | 4.78 | 4.39 |
| PS (TTM) | 5.32 | 134/215 | 6.37 | 6.02 | 5.55 |
| Dividend Yield | 0.53% | 127/215 | 0.53% | 0.50% | 0.47% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002826.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002826.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002826.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002826.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**